JMP Securities Maintains Market Outperform on Evolent Health, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Constantine Davides has maintained a Market Outperform rating on Evolent Health (NYSE:EVH) and increased the price target from $37 to $38.
February 23, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolent Health's price target has been raised from $37 to $38 by JMP Securities, with a maintained Market Outperform rating.
The increase in price target by JMP Securities reflects a positive outlook on Evolent Health's future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100